Secondly, phase II clinical trials such as SARC028 and ALLIANCE have shown the potential positive activity of anti‐PD‐L1 therapies in soft‐tissue sarcoma patients.32, 33. The gene discussed is CD274; the disease is soft tissue sarcoma.